Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Phase 2-3 Study in Japan
jRCT2080223419Phase 3Completed
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of risankizumab. Started Dec 2016; status: completed.
02
Drugs
risankizumab
Beyond the preview
Go deeper on jRCT2080223419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223419.